PharmaBioSource Realty provided real estate services to Eisai on the sale of its 60,000 SF Andover, Massachusetts high potency small molecule API pilot plant facility to Sarepta Therapeutics.

• Service: Real Estate
• Sector: Pharmaceuticals
• Sub-sector: Small Molecule API
• Engagement Type: Sell Side

PharmaBioSource Realty provided exclusive life sciences real estate services to divest Eisai’s high potency small molecule API pilot plant near Boston.  The facility was acquired by Cambridge, Massachusetts-based Sarepta Therapeutics. Sarepta acquired the facility to expand its manufacturing capabilities to support its Duchenne muscular dystrophy therapeutics research and manufacturing programs.

PharmaBioSource Realty’s services included a benchmark valuation, buyer target identification, creation of the confidential information memorandum (CIM), data room development and due diligence support.  The sale of the facility took only six months to complete from the initial marketing to closing.

Press Release